Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. reports clinical-stage oncology developments centered on targeted radiopharmaceuticals for solid tumors. The company’s miniprotein radioconjugate platform supports AKY-1189, a Nectin-4 program with potential across urothelial, breast, non-small cell lung, colorectal, cervical, and head and neck cancers, and AKY-2519, a B7-H3 program for prostate, lung, colorectal, and other solid tumors.
Recurring updates include FDA actions such as IND clearances and Fast Track designation, clinical-trial initiations, imaging and dosimetry data presentations, business and financial results, investor-conference participation, and board and committee changes. News also covers Aktis’ collaboration with Eli Lilly and Company to develop radioconjugates outside its proprietary pipeline.
Akoustis Technologies (NASDAQ: AKTS) announced five new Wi-Fi design wins, including four using Wi-Fi 6E and one using Wi-Fi 6 XBAW™ filters. These wins are expected to ramp into production and ship in 2022, increasing Akoustis' total design wins in Wi-Fi to 13. The company has also expanded its production capacity, targeting approximately 500 million filters annually at its New York facility. CEO Jeff Shealy highlighted continued momentum in the Wi-Fi segment due to performance advantages over competitors.
Akoustis Technologies (AKTS) reports a record revenue of $3.7 million for Q2 FY22, marking a 96% sequential increase. The company expects over 25% growth in the current quarter, driven by strong demand for its patented XBAW™ RF filter solutions across 5G and Wi-Fi markets. Five new design wins in Wi-Fi were announced, alongside a significant purchase order from a tier-1 5G mobile customer. As of December 31, 2021, Akoustis holds $67.5 million in cash. Despite ongoing challenges from COVID and semiconductor shortages, management forecasts continued growth due to a robust sales pipeline.
Akoustis Technologies, Inc. (NASDAQ: AKTS) will webcast its Q2FY22 results on January 31, 2022, at 8:00 am ET. The event includes a Q&A session. To participate by phone, call 877-407-3982 (domestic) or 201-493-6780 (international). The webcast will be available on the Company’s website. Akoustis is ramping up production, targeting an output of 500 million filters per year to meet increasing demand for 5G, Wi-Fi 6, and Wi-Fi 6E technologies.
The company is expanding its product lines in these areas, leveraging its cutting-edge XBAW™ technology.
Akoustis Technologies (NASDAQ: AKTS) announced that senior management will present at the 24th Annual Needham Growth Conference on January 10, 2022, at 2:45 PM ET. The conference will be held virtually due to COVID-19 precautions. Investors can access the presentation via the company's investor website. Akoustis is ramping production capacity at its New York facility to 500 million filters per year to meet growing demand for its 5G and WiFi 6E solutions.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced a purchase order from a new tier-1 module maker for the development of a 5G mobile XBAW filter. Initial samples are expected in the first half of CY22, with production ramp targeted for the second half of CY23. This collaboration marks the fourth active customer engagement for Akoustis' XBAW technology. The company aims to increase its annual production capacity to approximately 500 million filters, responding to growing demand in the 5G and WiFi markets.
Akoustis Technologies, Inc. (NASDAQ: AKTS) will present at the 2nd Annual Oppenheimer 5G Summit on December 14, 2021, at 9:05 am ET. Due to COVID-19 precautions, the event will be virtual. The presentation will be available on the investor website. Akoustis is ramping up production of its WiFi 6 and 5G filter solutions, targeting an annual capacity of approximately 500 million filters by the end of 2021. The company is actively engaged with customers to meet the growing demand for advanced RF filter technology.
Akoustis Technologies (NASDAQ: AKTS) announced that CEO Jeff Shealy will appear on TD Ameritrade Network today at 11:20 AM ET. The company is ramping up production of its WiFi 6 and 5G filter solutions, expecting to increase capacity at its New York facility to 500 million filters annually by the end of 2021. Akoustis aims to capture a share of the growing RF filter market with its proprietary XBAW™ technology, enhancing performance and bandwidth. The company is actively engaged with customers for expected sales growth in 2022.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced that Dave Aichele, EVP of Business Development, will present on "RF Acoustic Filters for High-Performance Wi-Fi" at the Wi-Fi Now Conference on November 17, 2021, at 1:25 PM ET. This virtual event is part of Akoustis's initiatives to enhance its Wi-Fi 6 and 5G filter solutions. The company plans to boost annual production capacity at its New York facility to 500 million filters by the end of 2021, addressing an increasing demand in the RF filter market.
Akoustis Technologies announced its fourth design win for patented WiFi 6E XBAW filters, set to be integrated into a new carrier-grade WiFi 6E gateway by a WiFi OEM. The solution will use 5.5 GHz and 6.5 GHz tandem filter modules for a 2X2 MU-MIMO carrier gateway product, with production expected to ramp up in the first half of 2022. This expansion aligns with the growing demand for high-performance coexistence filters following the FCC's approval of the 5.9 to 7.1 GHz bands for unlicensed use.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced its participation in the 10th Annual Roth Technology Conference on November 17, 2021. Due to Covid-19, the meetings will occur virtually. Investors interested in meetings can contact Akoustis' investor relations. The company is ramping up production capacity at its New York facility to 500 million RF filters per year, driven by demand for its WiFi 6 and 5G products. Akoustis aims to address the growing RF filter market with its innovative XBAW™ technology.